Amneal Pharmaceuticals (NYSE: AMRX) reported Q4 EPS of $0.33, $0.05 better than the analyst estimate of $0.28. Revenue for the quarter came in at $498 million versus the consensus estimate of $484.3 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2019 EPS of $0.94-$1.04, versus the consensus of $1.24.

• Adjusted EBITDA $600 million - $650 million

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.